News ReleaseDid some digging regarding what was in the news release and its significance.In the last 20 or so years no drug has recieved FDA approval - that did not show an objective partial response in its phase 1 human trials. Essentially if this was not shown your chances were the equivalent of 1 in 1000. However of the drugs that did get an objective partial response their approval chances increased to approx. 1 in 10. I wonder how many people selling are aware of this relationship.
This data is very good in that we are now looking at 3 ways that Exherin can be effective,
1. as a cocktail with chemo
2. as a VTA that destroys the cells surrounding the tumour by cutting off the blood supply and effectively starving the tumour and
3. which is the gem of the phase one trials - it is attacking the coreof the tumour itself
Although there have been critics as to how long this trial has taken the findings will be absolutely essential in stream lining the US and European trials that will not only save alot of precious $$'s -but also quicken the route to phase 3's and ultimately commercialization because if it.
Commissions
They now know to only target N-cadherin positive, they know how to release the dosage to eliminate side affects, and they now know that that Exherin is capable of affecting the tumour itself.